Table 1.
Patient demographic and clinical characteristics
| Feature | ICG Group(n = 40) | Metilen blue Group (n = 40) | p value |
|---|---|---|---|
| Age (years, mean ± SD) | 62.5 ± 8.1 | 61.8 ± 7.5 | 0.672 |
| BMI (kg/m², mean ± SD) | 28.7 ± 4.5 | 29.1 ± 4.2 | 0.719 |
| Parity (mean ± SD) | 2.1 ± 1.3 | 2.0 ± 1.2 | 0.805 |
| Postmenopausal (%) | 24 (60.0) | 25 (62.5) | 0.784 |
| Histological Type(%) | 0.553 | ||
| Endometrioid Adenocarcinoma | 32 (80.0) | 30 (75.0) | |
| Serous Adenocarcinoma | 5 (12.5) | 6 (15.0) | |
| Other | 3 (7.5) | 4 (10.0) | |
| Tumor Grade(%) | 0.611 | ||
| 1 | 18 (45.0) | 16 (40.0) | |
| 2 | 15 (37.5) | 17 (42.5) | |
| 3 | 7 (17.5) | 7 (17.5) | |
| FIGO Stage(%) | 0.829 | ||
| I | 37 (92.5) | 37 (92.5) | |
| II | 3 (7.5) | 3 (7.5) |